

Serial No: 09/512.363

Ref No: PF396P1

Bl (1988), and Derivan et al., Science 251:1300 (1991). The methods are based on binding of a polynucleotide to a complementary DNA or RNA.

In the Claims:

Please amend the claims as follows: 3

19. (Amended) A method of inhibiting binding of Endokine alpha to endogenous Endokine-alpha receptors in a mammal comprising administering to said mammal an effective amount of a TR11 polypeptide selected from the group consisting of:

- BS
- (a) a polypeptide whose amino acid sequence comprises amino acid residues -25-137 of SEQ ID NO:2;
 - (b) a polypeptide whose amino acid sequence comprises amino acid residues 1-137 of SEQ ID NO:2;
 - (c) a polypeptide whose amino acid sequence comprises amino acid residues 1-114 of SEQ ID NO:2;
 - BS
(d) a polypeptide whose amino acid sequence comprises amino acid residues -25-139 of SEQ ID NO:2;
 - (e) a polypeptide whose amino acid sequence comprises amino acid residues 21-139 of SEQ ID NO:2;
 - (f) a polypeptide whose amino acid sequence comprises amino acid residues 8-129 of SEQ ID NO:2;
 - (g) a polypeptide whose amino acid sequence comprises amino acid residues 8-48 of SEQ ID NO:2;
 - (h) a polypeptide whose amino acid sequence comprises amino acid residues 49-88 of SEQ ID NO:2; and
- B

Serial No: 09/512,363
Ref No: PF396P1

- (i) a polypeptide whose amino acid sequence comprises amino acid residues 89-129 of SEQ ID NO:2;
in a pharmaceutically acceptable carrier.

33. (Amended) A method of inhibiting binding of Endokine-alpha to endogenous Endokine-alpha receptors in a mammal comprising administering to said mammal an effective amount of a TR11 polypeptide selected from the group consisting of:

(a) a polypeptide whose amino acid sequence comprises amino acid residues residues -25-137 of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 209341;

(b) a polypeptide whose amino acid sequence comprises amino acid residues residues 1-137 of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 209341;

(c) a polypeptide whose amino acid sequence comprises amino acid residues 1-114 of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 209341;

(d) a polypeptide whose amino acid sequence comprises amino acid residues -25-139 of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 209341;

(e) a polypeptide whose amino acid sequence comprises amino acid residues 21-139 of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 209341;

(f) a polypeptide whose amino acid sequence comprises amino acid residues 8-129 of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 209341;

(g) a polypeptide whose amino acid sequence comprises amino acid residues 8-48 of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 209341;

Serial No: 09/512,363

Ref No: PF396P1

(h) a polypeptide whose amino acid sequence comprises amino acid residues 49-88 of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 209341; and

(i) a polypeptide whose amino acid sequence comprises amino acid residues 89-129 of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 209341;

in a pharmaceutically acceptable carrier.

~~16~~~~36.~~

(Amended)

The method of claim ~~15~~ wherein the mammal is a human.~~17~~~~37.~~

(Amended)

The method of claim ~~15~~ wherein the TR11 polypeptide is fused to a heterologous polypeptide.~~18~~~~38.~~

(Amended)

The method of claim ~~17~~ wherein the heterologous polypeptide is an immunoglobulin constant domain.~~19~~~~39.~~

(Amended)

The method of claim ~~18~~ wherein the immunoglobulin constant domain is an IgG1 constant domain.~~20~~~~40.~~

(Amended)

The method of claim ~~19~~ wherein the immunoglobulin constant domain is an IgG3 constant domain.~~21~~~~41.~~

(Amended)

The method of claim ~~17~~ wherein the heterologous polypeptide is human albumin.

Serial No: 08/517,363

Ref No: PF396P1

22
21. (Amended) The method of claim 15 wherein the pharmaceutically acceptable carrier is water.

23
21. (Amended) The method of claim 15 wherein the pharmaceutically acceptable carrier is saline.

24
21. (Amended) The method of claim 15 wherein the pharmaceutically acceptable carrier is Ringer's solution.

25
21. (Amended) The method of claim 15 wherein the pharmaceutically acceptable carrier is dextrose solution.

B6 cut
26
21. (Amended) The method of claim 15 wherein the pharmaceutically acceptable carrier is ethyl oleate.

27
21. (Amended) The method of claim 15 wherein the pharmaceutically acceptable carrier is a liposome.

28
21. (Amended) The method of claim 15 wherein the TR11 polypeptide inhibits T cell migration across endothelial cells.

47. (Amended) A method of inhibiting binding of Endokine-alpha to endogenous Endokine-alpha receptors in a mammal comprising administering to said mammal an effective amount of a polypeptide selected from the group consisting of:

255

B

Serial No. 09/512,363

Ref No: PF396P1

- (a) a polypeptide whose amino acid sequence comprises amino acid residues 1-162 of SEQ ID NO:4;
- (b) a polypeptide whose amino acid sequence comprises amino acid residues 1-162 of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 209342;
- (c) a polypeptide whose amino acid sequence comprises amino acid residues -19-149 of SEQ ID NO:6;
- (d) a polypeptide whose amino acid sequence comprises amino acid residues 1-149 of SEQ ID NO:6;
- (e) a polypeptide whose amino acid sequence comprises amino acid residues -19-149 of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 209343; and
- (f) a polypeptide whose amino acid sequence comprises amino acid residues 1-149 of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 209343; in a pharmaceutically acceptable carrier.
- Bb
cut

B